โ ๏ธ Caution: Stop immediately if rash, anaemia, bruising, fever, lymphadenopathy, or sore throat develop โ urgent medical review.
๐ Starting low and titrating slowly reduces the risk of severe rash (e.g. StevensโJohnson Syndrome, TEN).
๐ About
- Check BNF entry here for up-to-date dosing and monitoring guidance.
- Mechanism: stabilises neuronal membranes by inhibiting voltage-sensitive sodium channels and indirectly decreases glutamate release.
- Favourable cognitive profile compared with some other antiepileptics.
๐งพ Indications
- Partial seizures.
- Primary generalised tonicโclonic seizures.
- Juvenile myoclonic epilepsy.
- Secondary generalised seizures.
- Mood stabiliser (esp. in bipolar disorder, depressive relapse prevention).
๐ Dose (Adults)
- Weeks 1โ2: 25 mg PO on alternate days.
- Weeks 3โ4: 25โ50 mg daily.
- Titration: Increase by 25โ50 mg every 1โ2 weeks as tolerated.
- Maintenance: ~200 mg/day (range 100โ500 mg/day in divided doses).
- โ ๏ธ Interactions matter: halve dose if taking valproate; increase dose more rapidly if on enzyme inducers (e.g. carbamazepine, phenytoin).
๐ Interactions
- โ Carbamazepine levels (may cause toxicity).
- Valproate โ lamotrigine levels โ higher rash risk.
- Enzyme inducers (phenytoin, carbamazepine, rifampicin) โ lamotrigine levels.
- Always adjust dose depending on co-prescribed AEDs.
๐ฅ Side Effects
- Skin rash (within first 8 weeks) โ may progress to StevensโJohnson Syndrome or TEN โ stop immediately.
- Drowsiness, dizziness, diplopia, headache, insomnia.
- Psychiatric: agitation, anxiety, confusion, hallucinations.
- Haematological: bone marrow suppression โ โ Hb, WCC, platelets.
- Hepatotoxicity (rare).
๐งช Monitoring
- FBC, U&E, LFTs, and clotting at baseline and if symptoms develop.
- Monitor for rash closely during first 2 months.
- Caution in hepatic impairment (dose reduction needed).
๐ References
- BNF โ Lamotrigine
- NICE CG137: Epilepsies in children, young people and adults
- NICE CG185: Bipolar disorder